Trial
NCT05784129
A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Crohn's Disease
Intervention
Guselkumab
Why stopped
Janssen made an internal business decision to discontinue the PROGRESS study. This decision is not related to any efficacy or safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-29